We are pleased to share with you that WuXiPRA, a joint venture we formed together with PRA, has appointed Liedong Xu as its Executive Vice President and Chief Operations Officer and appointed Jason Wu as its Executive Vice President and Chief Medical Officer.   Liedong brings 22 years of experience in the pharmaceutical and medical device industries, including roles of increasing responsibility at MSD Allergan, Abbott Santen, and Merck Serono.  Jason brings 20 years of experience in clinical practice, clinical research, and product development include management positions at Graceway, Auxillium, Sanofi, and Pfizer.

WuXi PharmaTech and PRA formed the joint venture WuXiPRA in 2012 to provide comprehensive Phase I-IV clinical trial services in mainland China, Hong Kong and the Asia region.  Since then, WuXiPRA has grown to become the third largest clinical CRO in mainland China and Hong Kong, with over 400 employees.  We are very delighted to welcome Liedong and Jason on board to further strengthen WuXiPRA’s successful operations throughout China.


Related Links:

WuXi Makes New Management Appointments